Herein, we reported a case of spinal myoclonus following an ultrasound-guided suprascapular nerve block. A 58-year-old male patient who had a diagnosis of calcific tendinitis inside the right supraspinatus tendon received a right suprascapular nerve block (3 mL of 2% prilocaine mixed with 2 mL of 1% lidocaine) under the guidance of ultrasound. Sudden, painless, and involuntary movements began in the upper extremity 10 min after the intervention. Three months after the injection, the involuntary movements were entirely stopped. Involuntary, painless, and brief muscle jerks may be suggestive of myoclonus after interventions with local anesthetics.

Objectives: Fatigue and pain symptoms were common complaints among post-COVID-19 patients, and these lead to impaired quality of life (QoL). We aimed to evaluate severity of pain and fatigue 3 months after disease onset in discharged COVID-19 patients. Methods: Patients were contacted by phone at their third month following disease onset. Demographic data of the patients such as weight, height, body mass index (BMI), gender, smoking history, comorbidities, length of hospitalization, duration of stay in the intensive care unit, were recorded. The patients' pain and fatigue severities were evaluated by visual analog scale (VAS). QoL was questioned with the EuroQol Group Association five-domain, three-level questionnaire (EQ-5D-3L). Results: A total of 392 participants enrolled into the study. At admission, 94.6% of the participants had fatigue and 73.7% of them had pain. A high proportion of them still reported fatigue (55.1%) and pain (41.3%) at third month. The mean value of pain-VAS score was 5.37 ± 3.85, and it was 7.58 ± 2.82 for fatigue-VAS at admission. VAS scores of pain and fatigue at third month were 1.44 ± 2.11 and 2.04 ± 2.40 respectively. While 66.6% of the patients reported moderate-severe pain at disease onset, the rate was 18.1% at the third month. And also almost half had severe pain at admission (48%), it was 2.8% at third month. At disease onset 89.6% of the patients reported moderate-severe fatigue (severe: 48%). Aproximately one third of them had moderate-severe fatigue (27.9%) at third month (severe: 5.1%). The mean value of EQ-VAS score was 26.76 ± 20.26 at admission, and it was 78.84 ±16.15 at third month. Statistically significant differences were recorded between the disease onset and third month in terms of pain-VAS fatigue-VAS, and EQ-VAS scores (p < 0.001). Female gender, ICU admission, long duration of hospitalization, older age, higher BMI scores, multiple comorbidities, fatigue and pain severity were related to the decrease in QoL scores. Conclusions: Hospitalized COVID-19 survivors need ongoing support for pain, fatigue complaints and impaired QoL after discharge. The factors that cause poor QoL should be taken into account during post-COVID-19 follow up.

Objective: Osteoarthritis, a degenerative joint disease, often poses challenges in conventional medical treatment, leading patients to explore traditional and complementary medicine options including apitherapy. Bee venom, known for its analgesic and anti-inflammatory properties, has been considered as a potential therapy. This study investigates the short-term safety and effectiveness of applying live bee venom in knee osteoarthritis patients. Materials and Methods: Conducted at a university hospital's Apitherapy Clinic, this single-arm clinical trial enrolled individuals diagnosed with mild to moderate knee osteoarthritis (stage 2-3). A single session of live bee venom application was administered to acupuncture points ST35, EX-LE4, and ash-chi, specifically targeting the painful knee joint. Data collection involved the utilization of a Demographic Information Questionnaire and SF-12 Scale, along with a comparison of the Numerical Rating Scale (NRS), 5 Times Sit-to-Stand Test (5xSST), and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire before and after the treatment. Results: Before the treatment, the average NRS value stood at 7.14 ± 1.7, and following the intervention, it notably decreased to 3.06 ± 2.16 (p<0.05). Additionally, the mean value for the 5xSST decreased from 14.59 ± 3.36 before treatment to 11.75 ± 2.30 after treatment. The WOMAC scale also showed a significant difference between pre- and post-treatment (p<0.05), with the mean value decreasing from 41.91 ± 18.07 before treatment to 15.57 ± 15.14 after treatment. Conclusion: The findings of this study indicate a significant improvement in the NRS, 5xSST, and WOMAC scales after the administration of live bee venom for knee osteoarthritis patients.

Background: This study aimed to evaluate whether the magnesium depletion score (MDS), an indicator of magnesium deficiency, is associated with the development of complex regional pain syndrome type 1 (CRPS-1) in patients with traumatic extremity injuries. Patients and Methods: Between November 2024 and May 2025, a total of 117 patients who suffered from traumatic extremity injuries were included. Demographic and clinical data of the patients were collected and recorded, and the MDS was calculated. Age, sex, body mass index (BMI), smoking status, alcohol consumption, diabetes, hypertension, duration of immobilization, MDS, and injury-related characteristics were evaluated as potential risk factors for CRPS-1 development. Results: Of the patients, 40 were male and 77 were female with a mean age of 51.9 ± 15.01 (range, 20 to 91 years). In a total of 42.7% of patients with traumatic extremity injuries, CRPS-1 developed. The female-to-male ratio was higher among patients with CRPS-1 than among those without. The MDS, hypertension, diabetes, smoking, and alcohol consumption were not found to be independent risk factors. However, prolonged immobilization (more than one month) was found to be an independent risk factor for the development of CRPS-1. Conclusion: Our study results suggest that the MDS score is not a risk factor for developing CRPS-1, but immobilization for more than one month significantly increases the risk. Taken together, these findings indicate that the duration of immobilization following injury may be a more decisive factor in the development of CRPS-1 than demographic and clinical characteristics.

Objectives: The most common cause of shoulder pain is rotator cuff disease (RCD). Nocturnal pain is common in patients and is one of the main reasons for visiting a doctor. The aim of this study is to evaluate the effect of shoulder function and nocturnal pain on sleep quality in patients with RCD. Material and Methods: Ninety-three patients who presented to the outpatient clinic with RCD-related shoulder pain between October 2024 and December 2024 were included in the study. Shoulder function was assessed by the Penn Shoulder Score (PSS) and sleep quality by the Pittsburgh Sleep Quality Index (PSQI). Patients' magnetic resonance imaging (MRI) findings were recorded. Results: The mean PSQI score was 6.7±2.7. In the group with better sleep quality, the PSS was higher and the Penn Pain subscore was lower (p